High efficacy gold-KDEL peptide-siRNA nanoconstruct-mediated transfection in C2C12 myoblasts and myotubes

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 2, 2014, Pages 329-337

  Acharya, Suresh ^a   Hill, Rodney Allan ^a  

^a UNIVERSITY OF IDAHO   (United States)

Author keywords

Differentiation; Endocytosis; Gold nanoparticles; KDEL; Muscle; Peptide; SiRNA; Trafficking

Indexed keywords

DIFFERENTIATION; ENDOCYTOSIS; GOLD NANOPARTICLES; KDEL; MUSCLE; PEPTIDE; SIRNA; TRAFFICKING;

ANIMALS; CELL LINE; DRUG DELIVERY SYSTEMS; ENDOPLASMIC RETICULUM; GENE SILENCING; GOLD; GOLGI APPARATUS; METAL NANOPARTICLES; MICE; MUSCLE FIBERS, SKELETAL; MYOBLASTS; NADPH OXIDASE; NANOMEDICINE; OLIGOPEPTIDES; PEPTIDES; PROTEIN SORTING SIGNALS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84895070711     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.07.015     Document Type: Article

References (38)

1. Bergen J.M., von Recum H.A., Goodman T.T., Massey A.P., Pun S.H. Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol Biosci 2006, 6:506-516.
2. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008, 60:1307-1315.
3. Liu Y., Shipton M.K., Ryan J., Kaufman E.D., Franzen S., Feldheim D.L. Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide-poly(ethylene glycol) monolayers. Anal Chem 2007, 79:2221-2229.
4. Papasani M.R., Wang G.K., Hill R.A. Gold nanoparticles: the importance of physiological principles to devise strategies for targeted drug delivery. Nanomedicine 2012, 8:804-814.
5. Han G., Ghosh P., Rotello V.M. Functionalized gold nanoparticles for drug delivery. Nanomedicine (Lond) 2007, 2:113-123.
6. Lee S.H., Kim S.H., Park T.G. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem Biophys Res Commun 2007, 357:511-516.
7. Guo S., Huang Y., Jiang Q., Sun Y., Deng L., Liang Z., et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano 2010, 4:5505-5511.
8. Zhao E., Zhao Z., Wang J., Yang C., Chen C., Gao L., et al. Surface engineering of gold nanoparticles for in vitro siRNA delivery. Nanoscale 2012, 4:5102-5109.
9. Lee S.H., Bae K.H., Kim S.H., Lee K.R., Park T.G. Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers. Int J Pharm 2008, 364:94-101.
10. Lipka J., Semmler-Behnke M., Sperling R.A., Wenk A., Takenaka S., Schleh C., et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2011, 31:6574-6581.
11. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6:715-728.
12. Wangoo N., Bhasin K.K., Mehta S.K., Suri C.R. Synthesis and capping of water-dispersed gold nanoparticles by an amino acid: bioconjugation and binding studies. J Colloid Interface Sci 2008, 323:247-254.
13. Wang G.K., Papasani M.R., Cheguru P., Hrdlicka P.J., Hill R.A. Gold-peptide nanoconjugate cellular uptake is modulated by serum proteins. Nanomedicine 2012, 8:822-832.
14. Kim J.H., Jang H.H., Ryou S.M., Kim S., Bae J., Lee K., et al. A functionalized gold nanoparticles-assisted universal carrier for antisense DNA. Chem Commun (Camb) 2010, 46:4151-4153.
15. Liu Y., Mernaugh R.L., Zeng X. Single chain fragment variable recombinant antibody functionalized gold nanoparticles for a highly sensitive colorimetric immunoassay. Biosens Bioelectron 2009, 24:2853-2857.
16. Tkachenko A.G., Xie H., Liu Y., Coleman D., Ryan J., Glomm W.R., et al. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem 2004, 15:482-490.
17. Wang T., Bai J., Jiang X., Nienhaus G.U. Cellular uptake of nanoparticles by membrane penetration: a study combining confocal microscopy with FTIR spectroelectrochemistry. ACS Nano 2012, 6:1251-1259.
18. Pelham H.R. Recycling of proteins between the endoplasmic reticulum and Golgi complex. Curr Opin Cell Biol 1991, 3:585-591.
19. Townsley F.M., Wilson D.W., Pelham H.R. Mutational analysis of the human KDEL receptor: distinct structural requirements for Golgi retention, ligand binding and retrograde transport. EMBO J 1993, 12:2821-2829.
20. Orci L., Stamnes M., Ravazzola M., Amherdt M., Perrelet A., Sollner T.H., et al. Bidirectional transport by distinct populations of COPI-coated vesicles. Cell 1997, 90:335-349.
21. Wang G., Norton A.S., Pokharel D., Song Y., Hill R.A. KDEL peptide gold nanoconstructs: promising nanoplatforms for drug delivery. Nanomedicine 2013, 9:366-374.
22. Dancourt J., Barlowe C. Protein sorting receptors in the early secretory pathway. Annu Rev Biochem. 2010, 79:777-802.
23. Filipowicz W., Jaskiewicz L., Kolb F.A., Pillai R.S. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 2005, 15:331-341.
24. Gavrilov K., Saltzman W.M. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012, 85:187-200.
25. Acharya S., Peters A.M., Norton A.S., Murdoch G.K., Hill R.A. Change in Nox4 expression is accompanied by changes in myogenic marker expression in differentiating C2C12 myoblasts. Pflugers Arch 2013, 465:1181-1196.
26. Clemente C.F., Corat M.A., Saad S.T., Franchini K.G. Differentiation of C2C12 myoblasts is critically regulated by FAK signaling. Am J Physiol Regul Integr Comp Physiol 2005, 289:R862-R870.
27. Majmundar A.J., Skuli N., Mesquita R.C., Kim M.N., Yodh A.G., Nguyen-McCarty M., et al. O(2) regulates skeletal muscle progenitor differentiation through phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Biol 2012, 32:36-49.
28. Cheguru P., Chapalamadugu K.C., Doumit M.E., Murdoch G.K., Hill R.A. Adipocyte differentiation-specific gene transcriptional response to C18 unsaturated fatty acids plus insulin. Pflugers Arch 2012, 463:429-447.
29. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
30. Felgner P.L., Tsai Y.J., Sukhu L., Wheeler C.J., Manthorpe M., Marshall J., et al. Improved cationic lipid formulations for in vivo gene therapy. Ann N Y Acad Sci 1995, 772:126-139.
31. Romoren K., Thu B.J., Bols N.C., Evensen O. Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin. Biochim Biophys Acta 2004, 1663:127-134.
32. Zhong Y.Q., Wei J., Fu Y.R., Shao J., Liang Y.W., Lin Y.H., et al. Toxicity of cationic liposome Lipofectamine 2000 in human pancreatic cancer Capan-2 cells. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:1981-1984.
33. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006, 114:100-109.
34. Soenen S.J., Manshian B., Montenegro J.M., Amin F., Meermann B., Thiron T., et al. Cytotoxic effects of gold nanoparticles: a multiparametric study. ACS Nano. 2012, 6:5767-5783.
35. Duchardt F., Fotin-Mleczek M., Schwarz H., Fischer R., Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007, 8:848-866.
36. Shah N.B., Dong J., Bischof J.C. Cellular uptake and nanoscale localization of gold nanoparticles in cancer using label-free confocal Raman microscopy. Mol Pharm. 2011, 8:176-184.
37. Pichon C., Arar K., Stewart A.J., Dodon M.D., Gazzolo L., Courtoy P.J., et al. Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. Mol Pharmacol 1997, 51:431-438.
38. Zammit P.S., Relaix F., Nagata Y., Ruiz A.P., Collins C.A., Partridge T.A., et al. Pax7 and myogenic progression in skeletal muscle satellite cells. J Cell Sci 2006, 119:1824-1832.